iJRASET
International Journal For Research in Applied Science and Engineering Technology

INTERNATIONAL JOURNAL FOR RESEARCH

IN APPLIED SCIENCE & ENGINEERING TECHNOLOGY

Volume: 13 **Issue:** VI **Month of publication:** June 2025

DOI: https://doi.org/10.22214/ijraset.2025.72127

www.ijraset.com

Call: 08813907089 | E-mail ID: ijraset@gmail.com

International Journal for Research in Applied Science & Engineering Technology (IJRASET)
ISSN: 2321-9653; IC Value: 45.98; SJ Impact Factor: 7.538
Volume 13 Issue VI June 2025- Available at www.ijraset.com

Comparative Study of Ibuprofen Diclofenac Sodium & Indomethacin in NSAID

Ms. Darshana S. Saner[1], Ms. Shubhangee K. Patil[2], Mr. Shoaib Pinjari[3]
Aditya Institute of Pharmacy, Chalisgaon

Abstract: ***Non-steroidal anti-inflammatory medications are commonly used to treat fever, inflammation, and pain. Among them, the most commonly recommended medications are Indomethacin, Diclofenac Sodium, and Ibuprofen. The purpose of this review is to evaluate and contrast these three NSAIDs according to their safety, effectiveness, clinical applications, and pharmacological characteristics. It mainly works by preventing the creation of prostaglandins by blocking cyclooxygenase enzymes. Their therapeutic and side effect profiles are influenced by differences in these selectivities, though. Ibuprofen is widely accessible over-the-counter, has a good safety margin, and is frequently used for mild to severe discomfort. For inflammatory diseases like arthritis, diclofenac is commonly used since it is thought to be more effective. Because of its increased potential of adverse effects, the powerful NSAID indomethacin is primarily used to treat certain illnesses like gout and ankylosing spondylitis. The chemical classification, mode of action, pharmacokinetics, pharmacodynamics, clinical indications, and therapeutic comparisons of these medications are all examined in this article. Recent research and meta-analyses that shed light on the relative efficacy and tolerability of these medications are also examined in the review. In order to choose the best NSAID for each patient, taking into account comorbid diseases, side effects, and efficacy, it is essential to comprehend these variations. The development of NSAIDs in the future is also covered, with an emphasis on increasing effectiveness while lowering dangers to the heart, kidneys, and gastrointestinal tract.***

Keywords: NSAIDs, Ibuprofen, Diclofenac Sodium, Indomethacin, COX inhibitors, pharmacokinetics, pharmacodynamics, anti-inflammatory drugs

I. INTRODUCTION

The analgesic, antipyretic, and anti-inflammatory qualities of non-steroidal anti-inflammatory medicines (NSAIDs) make them one of the most widely used therapeutic agents in the world. These medications are crucial for treating a variety of ailments, from minor headaches to long-term inflammatory diseases like ankylosing spondylitis and rheumatoid arthritis. Because NSAIDs provide non-narcotic alternatives for pain management, their creation represented a major step in pharmacotherapy. Numerous NSAIDs with unique pharmacological characteristics are now available as a result of their discovery and subsequent modification over decades. Because of their accessibility and clinical effectiveness, Ibuprofen, Diclofenac Sodium, and Indomethacin have become important representatives among them. Despite having a similar mode of action, which is mainly the inhibition of cyclooxygenase (COX) enzymes, they differ in pharmacokinetics, potency, selectivity, and side-effect profiles, which makes them special for therapeutic use. Understanding the clinical positioning and pharmacological differences of these traditional agents is crucial when newer generations of NSAIDs with better safety profiles are produced[1-3].

In clinical practice, NSAID-induced gastropathy continues to be one of the most frequently reported adverse medication reactions. It becomes crucial in this situation to compare the relative risk profiles of indomethacin, diclofenac sodium, and ibuprofen. Diclofenac and Indomethacin are more powerful but come with greater dangers, whilst Ibuprofen is typically thought to be safer for gastrointestinal health. This means that while prescription NSAIDs, patient-specific considerations must be carefully taken into account. In this environment, personalised medicine approaches that consider underlying comorbidities and individual sensitivity to side effects are becoming more and more significant. Additionally, co-administration with gastroprotective drugs is being investigated as a way to reduce side effects without sacrificing effectiveness[4-5].

Optimising the clinical usage of these NSAIDs requires a thorough understanding of their pharmacokinetics and pharmacodynamics. Pharmacokinetics is a key factor in establishing dose regimens, frequency, and possible drug interactions. It also determines how medications are absorbed, distributed, metabolised, and excreted. Contrarily, pharmacodynamics investigates the physiological and biochemical impacts of medications as well as their modes of action. Ibuprofen is appropriate for over-the-counter use due to its balanced COX inhibition and brief half-life. Diclofenac has strong anti-inflammatory effects and is more selective for COX-2, however it should be used with caution in people who are at risk for cardiovascular problems. Despite its great

potency, indomethacin is linked to a higher risk of side effects, especially those involving the central nervous system and gastrointestinal tract. Each of these NSAIDs is specifically appropriate for certain clinical situations due to these pharmacological differences[6-7].

The clinical uses and therapeutic indications of various NSAIDs vary greatly in addition to their pharmacological characteristics. For common conditions like fever, toothache, menstrual cramps, and mild arthritis, ibuprofen is frequently prescribed. Diclofenac is used for illnesses including osteoarthritis and postoperative pain that involve a lot of inflammation and pain. Acute gout, ankylosing spondylitis, and neonatal patent ductus arteriosus (PDA) closure are among the disorders for which indomethacin is usually reserved. Making evidence-based decisions for customised patient care is made easier when one is aware of these signs. Additionally, prescribing decisions are influenced by each drug's relative cost, availability, and patient compliance. Affordability and accessibility, rather than clinical fit, may frequently determine the choice of NSAID in resource-constrained settings, creating further obstacles to the best possible treatment[8-10].

II. CHEMICAL STRUCTURE AND CLASSIFICATION[11-12]

A. *Classification of NSAIDs*

1) Salicylates: Aspirin, Sodium salicylate
2) Propionic Acid Derivatives: Ibuprofen, Naproxen, Ketoprofen
3) Acetic Acid Derivatives: Diclofenac Sodium, Indomethacin, Sulindac
4) Enolic Acid Derivatives (Oxicams): Piroxicam, Meloxicam
5) Fenamates (Anthranilic Acid Derivatives): Mefenamic acid
6) Selective COX-2 Inhibitors (Coxibs): Celecoxib, Etoricoxib

B. *Chemical Structures13-15*

- Ibuprofen: Propionic acid derivative with an iso buty lphenyl group
- Diclofenac Sodium: Acetic acid derivative with two chlorine-substituted phenyl rings
- Indomethacin: Acetic acid derivative with an indole acetic acid core

III. MECHANISM OF ACTION[16-17]

Table.1: Mechanism of action

Drug Name	COX Inhibition	COX Selectivity	Resulting Effect
Ibuprofen	COX-1 and COX-2	Non-selective	Reduces prostaglandin synthesis, lowering inflammation and pain
Diclofenac	COX-1 and COX-2	COX-2 > COX-1	Strong anti-inflammatory action with cardiovascular risks
Indomethacin	COX-1 and COX-2	Non-selective	Potent anti-inflammatory and analgesic, more GI side effects

Mechanism Explanation: NSAIDs inhibit the cyclooxygenase (COX) enzymes, particularly COX-1 and COX-2, which are essential for the conversion of arachidonic acid to prostaglandins and thromboxanes. These mediators are responsible for inflammation, pain, and fever. Inhibition of COX-1 may lead to gastrointestinal and renal side effects, while COX-2 inhibition contributes to anti-inflammatory effects.

IV. PHARMAOKINETICS[18-19]

Table.2: Pharmacokinetics

Parameter	Ibuprofen	Diclofenac Sodium	Indomethacin
Absorption	Rapid, oral bioavailability ~80%	Rapid, oral bioavailability ~50-60%	Rapid, oral bioavailability ~100%
Protein Binding	> 99%	> 99%	> 99%
Metabolism	Hepatic (CYP2C9)	Hepatic (CYP2C9, CYP3A4)	Hepatic
Elimination Half-life	2–4 hours	1–2 hours	4.5 hours
Excretion	Renal (mostly unchanged)	Renal and biliary	Renal and fecal

ISSN: 2321-9653; IC Value: 45.98; SJ Impact Factor: 7.538
Volume 13 Issue VI June 2025- Available at www.ijraset.com

V. PHARMACODYNAMICS[20-21]:

1) Ibuprofen: Reversibly inhibits both COX-1 and COX-2 enzymes, leading to decreased synthesis of prostaglandins. This results in reduced pain, inflammation, and fever. It has a relatively mild effect on platelet aggregation.
2) Diclofenac Sodium: Acts predominantly on COX-2, offering strong anti-inflammatory effects. It also reduces prostaglandin E2 levels in inflamed tissues, effectively decreasing inflammation and associated pain. Its selectivity for COX-2 increases cardiovascular risk.
3) Indomethacin: A potent non-selective COX inhibitor, resulting in strong suppression of prostaglandin synthesis. It has notable central and peripheral anti-inflammatory effects but carries a higher risk for GI and CNS side effects.

VI. CLINICAL INDICATION[22-23]:

A. Ibuprofen

- Mild to moderate pain (e.g., headache, dental pain, dysmenorrhea)
- Fever
- Osteoarthritis and rheumatoid arthritis
- Musculoskeletal disorders
- Inflammatory conditions such as bursitis and tendonitis

B. Diclofenac Sodium

- Acute and chronic treatment of osteoarthritis and rheumatoid arthritis
- Ankylosing spondylitis
- Postoperative and traumatic pain
- Dysmenorrhea
- Migraine (as potassium salt)

C. *Indomethacin*

- Moderate to severe rheumatoid arthritis and osteoarthritis
- Ankylosing spondylitis
- Acute gouty arthritis
- Patent ductus arteriosus (PDA) closure in neonates
- Tendonitis and bursitis

VII. COMPARTIVE STUDY OF IBUPROFEN DICLOFENAC SODIUM & INDOMETHACIN IN NSAIDS[24-25]:

Table.3: Comparative study

Parameter	Ibuprofen	Diclofenac Sodium	Indomethacin
Drug Class	Propionic acid derivative	Acetic acid derivative	Acetic acid derivative
COX Selectivity	Non-selective	COX-2 > COX-1	Non-selective
Analgesic Efficacy	Moderate	High	High
Anti-inflammatory Action	Moderate	Strong	Very strong
GI Side Effects	Low	Moderate	High
Cardiovascular Risk	Low	Higher	Moderate
Renal Impact	Mild	Moderate	Moderate to severe
Indications	Mild-moderate pain, fever	Arthritis, pain, dysmenorrhea	Arthritis, gout, PDA closure
Dosing Frequency	3–4 times/day	2–3 times/day	2–3 times/day
Safety Profile	Good	Moderate	Poor (more side effects)

VIII. FUTURE SCOPE OF STUDY[26-27]

The evolving landscape of NSAID research emphasizes the urgent need for safer, more effective anti-inflammatory agents with minimal side effects. Future investigations into ibuprofen, diclofenac sodium, and indomethacin will likely focus on their molecular interactions, personalized medicine applications, and novel drug delivery systems. For instance, formulating these NSAIDs using nanotechnology or transdermal systems may enhance bioavailability while reducing gastrointestinal and cardiovascular risks.

Advancements in pharmacogenomics also offer significant potential. Identifying genetic markers related to NSAID metabolism and sensitivity could lead to personalized therapy, optimizing drug selection and dosage. Such approaches aim to balance efficacy with safety, particularly in vulnerable populations like the elderly, children, and patients with comorbidities.

Additionally, the integration of herbal and synthetic drug combinations presents an innovative pathway. Combining NSAIDs with plant-based anti-inflammatory agents may synergistically enhance therapeutic outcomes while minimizing toxicity. Research into COX-2 selective derivatives with lower cardiovascular impacts is also a promising area.

Regulatory perspectives are shifting towards stricter post-marketing surveillance to track long-term adverse effects. This will demand real-world evidence and longitudinal studies, ensuring safer public health outcomes. As we move forward, the focus will increasingly be on sustainability in drug production, eco-friendly synthesis, and cost-effectiveness.

In summary, the future of NSAID research lies in precision medicine, safer formulations, and integrative approaches that bridge conventional pharmacology with modern innovation.

IX. CONCLUSION

In conclusion, the comparative evaluation of ibuprofen, diclofenac sodium, and indomethacin provides valuable insights into their pharmacological profiles, therapeutic uses, and safety considerations. Ibuprofen remains a widely accepted over-the-counter NSAID for mild to moderate pain and fever due to its favorable safety profile and minimal gastrointestinal and cardiovascular side effects. Diclofenac sodium, although more potent in its anti-inflammatory effects, requires cautious use owing to its associated cardiovascular risks, especially with long-term therapy. Indomethacin stands out for its strong anti-inflammatory and analgesic properties, making it particularly effective in conditions like gout and rheumatoid arthritis; however, its higher incidence of gastrointestinal and central nervous system side effects limits its broader applicability.

The pharmacokinetic and pharmacodynamic differences among these NSAIDs dictate their clinical applications, dosing frequencies, and side effect profiles. While non-selective COX inhibition offers broad anti-inflammatory benefits, selective COX-2 inhibition, as seen in diclofenac to some extent, underscores the need to balance efficacy with cardiovascular safety. As research advances, personalized NSAID therapy guided by pharmacogenomics may become integral to clinical practice, optimizing efficacy and minimizing adverse outcomes.

In light of ongoing drug development and formulation innovations, these NSAIDs continue to hold clinical significance. However, there is a growing need to explore safer derivatives, alternative delivery systems, and combination therapies to enhance therapeutic outcomes. Thus, continued research and post-market surveillance are essential to ensure patient safety, therapeutic success, and the evolution of evidence-based clinical guidelines.

REFERENCES

[1] Brune, K., & Patrignani, P. (2015). New insights into the use of currently available non-steroidal anti-inflammatory drugs. Journal of Pain Research, 8, 105–118.
[2] Davies, N. M. (1998). Clinical pharmacokinetics of ibuprofen: The first 30 years. Clinical Pharmacokinetics, 34(2), 101–154.
[3] Hinz, B., & Brune, K. (2002). Cyclooxygenase-2–10 years later. Journal of Pharmacology and Experimental Therapeutics, 300(2), 367–375.
[4] Hawkey, C. J. (2001). COX-2 inhibitors. The Lancet, 353(9149), 307–314.
[5] McGettigan, P., & Henry, D. (2011). Cardiovascular risk with non-steroidal anti-inflammatory drugs: Systematic review of population-based controlled observational studies. PLoS Medicine, 8(9), e1001098.
[6] Wallace, J. L. (2008). Prostaglandins, NSAIDs, and gastric mucosal protection: Why doesn't the stomach digest itself? Physiological Reviews, 88(4), 1547–1565.
[7] Rainsford, K. D. (2009). Ibuprofen: Pharmacology, efficacy and safety. Inflammopharmacology, 17(6), 275–342.
[8] Bindu, S., Mazumder, S., & Bandyopadhyay, U. (2020). Non-steroidal anti-inflammatory drugs (NSAIDs) and organ damage: A current perspective. Biochemical Pharmacology, 180, 114147.
[9] Moore, N., Pollack, C., & Butkerait, P. (2015). Adverse drug reactions and drug–drug interactions with over-the-counter NSAIDs. Therapeutics and Clinical Risk Management, 11, 1061–1075.
[10] Patrono, C., & Baigent, C. (2014). Nonsteroidal anti-inflammatory drugs and the heart. Circulation, 129(8), 907–916.
[11] Crofford, L. J. (2013). Use of NSAIDs in treating patients with arthritis. Arthritis Research & Therapy, 15(S3), S2.

[12] Bjarnason, I., Scarpignato, C., Takeuchi, K., & Rainsford, K. D. (2007). Determinants of the short-term gastric damage caused by NSAIDs in man. Alimentary Pharmacology & Therapeutics, 26(1), 95–106.
[13] Farkouh, M. E., Greenberg, J. D., & Jeger, R. V. (2017). Cardiovascular safety of nonsteroidal anti-inflammatory drugs: Current state of evidence. Current Cardiology Reports, 19(5), 20.
[14] Simon, L. S. (1999). Role and regulation of cyclooxygenase-2 during inflammation. American Journal of Medicine, 106(5), 37S–42S.
[15] Zidar, N., & Bonaca, M. P. (2018). NSAIDs and cardiovascular risk: Current perspectives. Current Cardiology Reports, 20(10), 85.
[16] Derry, S., Moore, R. A., & McQuay, H. J. (2015). Single dose oral ibuprofen for acute postoperative pain in adults. Cochrane Database of Systematic Reviews, 2015(7), CD001548.
[17] Scharf, J. Y., & Uhl, K. (2003). Risk assessment of NSAIDs in the elderly. Drugs & Aging, 20(7), 529–543.
[18] Motsko, S. P., Rascati, K. L., Busti, A. J., & Cziraky, M. J. (2006). Temporal patterns of NSAID use and risk of gastrointestinal complications. Pharmacotherapy, 26(10), 1427–1436.
[19] Wehling, M. (2014). Non-steroidal anti-inflammatory drug use in chronic pain conditions. Drugs & Aging, 31(6), 469–472.
[20] Levesque, L. E., Brophy, J. M., & Zhang, B. (2005). The risk for myocardial infarction with cyclooxygenase-2 inhibitors. The Lancet, 365(9454), 475–481.
[21] Roelofs, M. M., Deyo, R. A., Koes, B. W., Scholten, R. J., & van Tulder, M. W. (2008). Non-steroidal anti-inflammatory drugs for low back pain. Cochrane Database of Systematic Reviews, 2008(1), CD000396.
[22] Derry, S., Rabbie, R., & Moore, R. A. (2013). Diclofenac for acute postoperative pain in adults. Cochrane Database of Systematic Reviews, 2013(2), CD004768.
[23] Whelton, A. (1999). Nephrotoxicity of nonsteroidal anti-inflammatory drugs: Physiologic foundations and clinical implications. American Journal of Medicine, 106(5), 13S–24S.
[24] Laine, L. (2001). Approaches to nonsteroidal anti-inflammatory drug use in the high-risk patient. Gastroenterology, 120(3), 594–606.
[25] Bombardier, C., Laine, L., Reicin, A., et al. (2000). Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. New England Journal of Medicine, 343(21), 1520–1528.
[26] Griffin, M. R. (1998). Epidemiology of nonsteroidal anti-inflammatory drug–associated gastrointestinal injury. American Journal of Medicine, 104(3), 23S–29S.
[27] Mukherjee, D., Nissen, S. E., & Topol, E. J. (2001). Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA, 286(8), 954–959.
[28] Cheng, Y., Austin, S. C., Rocca, B., et al. (2002). Role of prostacyclin in the cardiovascular response to thromboxane A2. Science, 296(5567), 539–541.
[29] Bjarnason, I., & Takeuchi, K. (2009). Intestinal permeability and NSAIDs. Gut, 58(10), 1334–1336.
[30] Silverstein, F. E., Faich, G., Goldstein, J. L., et al. (2000). Gastrointestinal toxicity with celecoxib vs. nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis. JAMA, 284(10), 1247–1255.



10.22214/IJRASET

45.98

IMPACT FACTOR: 7.129

IMPACT FACTOR: 7.429

INTERNATIONAL JOURNAL FOR RESEARCH

IN APPLIED SCIENCE & ENGINEERING TECHNOLOGY